Litigation And Financial OutlookCureVac has settled disputes with Acuitas, reducing the number of U.S. patents and German utility models in litigation, and management expects limited future expenses for this program, maintaining a cash runway expectation into Q4 2025.
Strategic PartnershipsCureVac announced a co-development and licensing agreement to create mRNA-based cancer vaccines for hematological and solid cancers with high unmet need, with MD Anderson conducting initial Phase 1/2 studies.
Vaccine DevelopmentThe Phase 1/2 trial for an mRNA vaccine for H5N1 bird flu is advancing in partnership with GSK, and the candidate has received Fast Track designation from the FDA.